POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium is the major intracellular cation necessary for nerve conduction, muscle contraction, and acid-base balance. Chloride is the major extracellular anion and helps maintain osmotic pressure and acid-base balance. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid volume and electrolyte balance.
| Metabolism | Potassium is excreted primarily by the kidneys; metabolism not applicable as it is an electrolyte. |
| Excretion | Renal: >90% of potassium is excreted by the kidneys, primarily via distal tubular secretion. Fecal: <10% (minor route). Biliary: negligible. |
| Half-life | Potassium has a functional half-life of approximately 2-4 hours for distribution, but terminal elimination is not defined due to rapid renal excretion and homeostatic regulation. In states of normal renal function, excess potassium is cleared within hours. |
| Protein binding | Potassium is not bound to plasma proteins (<1%). |
| Volume of Distribution | Approximately 0.5-0.6 L/kg, reflecting distribution primarily in extracellular fluid (ECF). Total body potassium is ~50 mEq/kg, but Vd for administered potassium is largely limited to ECF until intracellular uptake occurs. |
| Bioavailability | Intravenous: 100% (only route for this formulation). No oral bioavailability as this is an IV solution. |
| Onset of Action | Intravenous: Onset is immediate upon infusion; clinical effect on serum potassium occurs within minutes. No other routes for this formulation. |
| Duration of Action | Intravenous infusion: Duration is limited to the infusion period and short-lived after cessation; redistribution and excretion begin immediately. Continuous infusion required for sustained effect. Does not provide prolonged duration. |
| Molecular Weight | 74.55 |
Intravenous infusion, typical dose is 10 mEq/hour (as potassium chloride 0.3% in sodium chloride 0.9%) at a rate not exceeding 10 mEq/hour for maintenance; maximum 20 mEq/hour in severe deficiency with cardiac monitoring.
| Dosage form | INJECTABLE |
| Renal impairment | Avoid use if GFR < 30 mL/min/1.73 m² due to risk of hyperkalemia. For GFR 30-50 mL/min/1.73 m², reduce dose by 50% and monitor serum potassium frequently. |
| Liver impairment | No specific dose adjustment for Child-Pugh A or B; for Child-Pugh C (severe hepatic impairment), consider potassium-sparing agents and reduce dose by 50% due to increased risk of hyperkalemia. |
| Pediatric use | Intravenous infusion: 0.5-1 mEq/kg/dose (max 1 mEq/kg) infused over 1-2 hours, not to exceed 0.5 mEq/kg/hour; monitor serum potassium and ECG. |
| Geriatric use | Initiate at lower end of adult dosing (e.g., 5 mEq/hour) with careful monitoring of serum potassium and renal function due to age-related decreased GFR and risk of hyperkalemia. |
| 1st trimester | Potassium chloride and sodium chloride are essential electrolytes. Use only if clearly needed and if hypokalemia or hyponatremia is documented. No known teratogenicity at therapeutic doses. |
| 2nd trimester | Safe for use when indicated for electrolyte replacement. Monitor serum electrolytes regularly. |
| 3rd trimester | Safe for use when indicated. Avoid excessive doses to prevent maternal hyperkalemia/hypernatremia, which could affect fetal electrolyte balance. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium and chloride ions cross the placenta by active transport and diffusion to maintain fetal electrolyte homeostasis. Sodium crosses readily. No evidence of adverse fetal effects at physiological concentrations. |
| Breastfeeding | Potassium and sodium are normal constituents of breast milk. Intravenous administration does not pose a risk to the nursing infant. Monitor maternal serum electrolytes to avoid imbalance. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride and sodium chloride are normal body constituents. No teratogenic effects are expected when used appropriately. In all trimesters, there is no known risk of fetal harm from physiologic doses. Overdose or hyperkalemia/hypernatremia may cause maternal complications with secondary fetal effects. |
| Fetal Monitoring | Monitor serum potassium and sodium levels, renal function, and acid-base status. In pregnancy, monitor for signs of hyperkalemia (ECG changes, arrhythmias) or hypernatremia (fluid overload, hypertension). Fetal surveillance as appropriate for maternal condition. |
| Fertility Effects | No known adverse effects on fertility. Normal electrolyte balance is essential for reproductive function; severe disturbances may impair fertility indirectly. |
■ FDA Black Box Warning
None
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHypernatremiaSevere renal impairment with oliguria or anuriaHypersensitivity to any component
| Precautions | Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia, Monitor serum potassium levels during therapy, Avoid rapid infusion to prevent hyperkalemia and cardiac arrest, Do not administer in concentrated solutions via peripheral vein |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, potatoes, spinach) and salt substitutes containing potassium; do not take potassium supplements without medical approval. |
| Clinical Pearls | Administer via central line if concentration > 0.2% KCI to avoid phlebitis; maximum infusion rate typically 10 mEq/hour; monitor serum potassium and ECG continuously; contraindicated in severe hyperkalemia. |
| Patient Advice | Report any pain, redness, or swelling at IV site immediately. · Do not adjust the IV rate or stop the infusion on your own. · Inform your doctor if you have kidney problems or are taking potassium-sparing diuretics. · Avoid potassium-rich foods and supplements unless approved by your doctor. |
Loading safety data…